Search research articles
Contact Us
Filters
Showing results (11-20 of 36) with videos related to
Page
of 4
Sort By:
Nucleic Acids Research
|
April 23, 2025
DirectHRD enables sensitive scar-based classification of homologous recombination deficiency
Ruolin Liu, Eugenia Roberts, Heather A Parsons, et al.
Blood
|
July 21, 2005
The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo
Elizabeth H Stover, Jing Chen, Benjamin H Lee, et al.
Gynecologic Oncology
|
July 2, 2026
Toward precision prognosis: Predicting recurrence-free survival in high-grade serous ovarian cancer patients using multi-time point clinical and computed tomography radiomics data
Lauren Roller, Ningxuan Zhou, Isha Atre, et al.
JCO Precision Oncology
|
December 7, 2023
Endometrial Cancer Risk Among Germline <i>BRCA1</i>/<i>2</i> Pathogenic Variant Carriers: Review of Our Current Understanding and Next Steps
Kimia Sorouri, Filipa Lynce, Colleen M Feltmate, et al.
Cell Stem Cell
|
June 6, 2009
Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis
Inga Hofmann, Elizabeth H Stover, Dana E Cullen, et al.
JCO Precision Oncology
|
January 20, 2022
Clinical Pan-Cancer Assessment of Mismatch Repair Deficiency Using Tumor-Only, Targeted Next-Generation Sequencing
Adem Albayrak, Ana C Garrido-Castro, Marios Giannakis, et al.
Genome Medicine
|
May 21, 2021
Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer
Zachary T Weber, Katharine A Collier, David Tallman, et al.
Cell Reports
|
December 13, 2018
PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
Liya Ding, Hye-Jung Kim, Qiwei Wang, et al.
Gynecologic Oncology
|
August 11, 2020
Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial
Elizabeth K Lee, Niya Xiong, Su-Chun Cheng, et al.
Nature Communications
|
March 27, 2026
Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trial
Rebecca L Porter, Yinglu Zhou, Nebiyat Eskndir, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 36) with videos related to
Sort By:
Page
of 4
Nucleic Acids Research
|
April 23, 2025
DirectHRD enables sensitive scar-based classification of homologous recombination deficiency
Ruolin Liu, Eugenia Roberts, Heather A Parsons, et al.
Blood
|
July 21, 2005
The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo
Elizabeth H Stover, Jing Chen, Benjamin H Lee, et al.
Gynecologic Oncology
|
July 2, 2026
Toward precision prognosis: Predicting recurrence-free survival in high-grade serous ovarian cancer patients using multi-time point clinical and computed tomography radiomics data
Lauren Roller, Ningxuan Zhou, Isha Atre, et al.
JCO Precision Oncology
|
December 7, 2023
Endometrial Cancer Risk Among Germline <i>BRCA1</i>/<i>2</i> Pathogenic Variant Carriers: Review of Our Current Understanding and Next Steps
Kimia Sorouri, Filipa Lynce, Colleen M Feltmate, et al.
Cell Stem Cell
|
June 6, 2009
Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis
Inga Hofmann, Elizabeth H Stover, Dana E Cullen, et al.
JCO Precision Oncology
|
January 20, 2022
Clinical Pan-Cancer Assessment of Mismatch Repair Deficiency Using Tumor-Only, Targeted Next-Generation Sequencing
Adem Albayrak, Ana C Garrido-Castro, Marios Giannakis, et al.
Genome Medicine
|
May 21, 2021
Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer
Zachary T Weber, Katharine A Collier, David Tallman, et al.
Cell Reports
|
December 13, 2018
PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
Liya Ding, Hye-Jung Kim, Qiwei Wang, et al.
Gynecologic Oncology
|
August 11, 2020
Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial
Elizabeth K Lee, Niya Xiong, Su-Chun Cheng, et al.
Nature Communications
|
March 27, 2026
Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trial
Rebecca L Porter, Yinglu Zhou, Nebiyat Eskndir, et al.
Page
of 4